Prostate cancer: What is the future role for imaging?

American Journal of Roentgenology

Volumn 176, Issue 1, 2001, Pages 17-22

  Thornbury, J R ^a   Ornstein, D K ^a   Choyke, P L ^a   Langlotz, C P ^a   Weinreb, J C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; IMAGING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MEDICINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0035182543     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.176.1.1760017     Document Type: Review

References (64)

1. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves
2. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements
3. Longitudinal screening for prostate cancer with prostate specific antigen
4. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
5. Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen
6. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
7. Prostate-specific antigen as a screening test for prostate cancer: The United States experience
8. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
9. Prostate-specific antigen testing for early diagnosis of prostate cancer: Formulation of guidelines
10. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer
11. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values
12. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer
13. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
14. Pain and morbidity of transrectal ultrasound guided prostate biopsy: A prospective randomized trial of six versus 12 cores
15. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
16. Results of radical prostatectomy in men with clinically localized prostate cancer
17. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
18. Long-term cancer patient survival in the United States
19. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
20. The National Cancer Data Base report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S.
21. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
22. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediateterm results
23. Natural history of progression after PSA elevation following radical prostatectomy
24. Evidence for a prostate cancer-susceptibility locus on chromosome 20
25. A genomic scan of families with prostate cancer identifies multiple regions of interest
26. Transrectal ultrasound of the prostate: Innovations and future applications
27. Clinical applications of ultrasound contrast agents
28. Contrast angiosonography: A technology to improve Doppler ultrasound examinations of the prostate
29. Prospective evaluation of endorectal magnetic resonance imaging to detect minor foci in men with prior negative prostatic biopsy: A pilot study
30. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease
31. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy
32. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma
33. Citrate in the diagnosis of prostate cancer
34. Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging: Clinicopathologic study
35. The classification of benign and malignant human prostate tissue by multivariate analysis of H-1 magnetic resonance spectra
36. Dynamic turboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results
37. Magnetic resonance elastography of the prostate
38. MR lymphangiography using ultrasmall super-paramagnetic iron oxide in patients with primary abdominal and pelvic malignancies: Radiographic-pathologic correlation
39. Synthesis and relaxometry of high-generation (G=5, 7, 9 and 10) PAMAM dendrimer-DOTA-gadolinium chelates
40. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma
41. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy
42. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
43. Capromab pendetide: A review of its use as an imaging agent in prostate cancer
44. Monoclonal antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen?
45. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
46. PET imaging of prostate cancer using carbon-11 choline
47. Three-dimensional spectral spatial EPR imaging of free radicals in the heart: A technique for imaging tissue metabolism and oxygenation
48. Optical imaging in medicine. 1. Experimental techniques
49. Positive surgical margins at radical prostatectomy: Importance of the apical dissection
50. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: Results of a multi-institutional cooperative trial
51. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
52. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
53. Staging of prostatic cancer: Accuracy of MR imaging
54. Staging of prostatic cancer: Accuracy of MR imaging (devil's advocate)
55. The use of endorectal MR imaging to predict prostate carcinoma recurrence after radical prostatectomy
56. The future of research in genitourinary radiology: Through the looking glass - A view from the Society of Uroradiology
57. A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Research Team
58. 3) spatial resolution
59. Human prostate: Multisection proton MR spectroscopic imaging with a single spin-echo sequence-preliminary experience
60. Prostate cancer: Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging
61. Localizing prostate cancer in the presence of postbiopsy changes on MR images: Role of proton MR spectroscopic imaging
62. Intermediate outcomes: Diagnostic and therapeutic impact
63. American College of Radiology Imaging Network: New national cooperative group for conducting clinical trials of medical imaging technologies
64. Costs and benefits of MR imaging of prostate cancer